• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mallinckrodt - Articles and news items

muscular-dystrophy

Mallinckrodt’s muscular dystrophy drug receives FDA fast track designation

Industry news / 26 August 2016 / Niamh Louise Marriott, Digital Content Producer

For the treatment of Duchenne muscular dystrophy (DMD), Synacthen Depot is a synthetic 24 amino acid melanocortin receptor agonist. Outside the US, it…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +